Skip to main content
SpringerLink
Log in

Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review

  • Protocol
  • First Online:
Precision Medicine

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2204))

Abstract

Epstein–Barr virus (EBV) is a B-lymphocytes herpes virus and can transform B lymphocytes to malignant tumor cells if infected. Nasopharyngeal carcinoma (NPC) is strongly associated with EBV. Circulating EBV DNA in plasma has been recognized as an important biomarker of NPC. Much work has been done to validate the ability of circulating EBV DNA for screening, diagnosis, risk stratification, monitoring, and predicting prognosis. This chapter reviews the clinical progress of circulating cell-free EBV DNA in NPC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chen YP, Chan ATC, Le QT et al (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64–80

    Article  PubMed  Google Scholar 

  2. Chua MLK, Wee JTS, Hui EP et al (2016) Nasopharyngeal carcinoma. Lancet 387(10022):1012–1024

    Article  PubMed  Google Scholar 

  3. Guo R, Tang LL, Mao YP et al (2019) Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 125(1):79–89

    Article  CAS  PubMed  Google Scholar 

  4. Lin JC, Wang WY, Chen KY et al (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350(24):2461–2470

    Article  CAS  PubMed  Google Scholar 

  5. Lo YM, Chan LY, Lo KW et al (1999) Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59(6):1188–1191

    CAS  PubMed  Google Scholar 

  6. Qu H, Huang Y, Zhao S et al (2020) Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol 277(1):9–18

    Article  PubMed  Google Scholar 

  7. Lam WKJ, Chan KCA, Lo YMD (2019) Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J Pathol 247(5):641–649

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chan KCA, Woo JKS, King A et al (2017) Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 377(6):513–522

    Article  CAS  PubMed  Google Scholar 

  9. Lee VH, Kwong DL, Leung TW et al (2019) The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer 144(7):1713–1722

    Article  CAS  PubMed  Google Scholar 

  10. Shotelersuk K, Khorprasert C, Sakdikul S et al (2000) Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 6(3):1046–1051

    CAS  PubMed  Google Scholar 

  11. To EW, Chan KC, Leung SF et al (2003) Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9(9):3254–3259

    CAS  PubMed  Google Scholar 

  12. Lo YM, Leung SF, Chan LY et al (2000) Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 60(9):2351–2355

    CAS  PubMed  Google Scholar 

  13. Yip TT, Ngan RK, Fong AH et al (2014) Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol 50(6):527–538

    Article  CAS  PubMed  Google Scholar 

  14. Chan AT, Lo YM, Zee B et al (2002) Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94(21):1614–1619

    Article  CAS  PubMed  Google Scholar 

  15. Zhang Y, Tang LL, Li YQ et al (2019) Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis. Int J Cancer 144(9):2313–2319

    Article  CAS  PubMed  Google Scholar 

  16. Makitie AA, Reis PP, Irish J et al (2004) Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck 26(9):815–822

    Article  PubMed  Google Scholar 

  17. Peng H, Li Z, Long Y et al (2019) Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis. Biosci Rep:39(9)

    Google Scholar 

  18. Ng RH, Ngan R, Wei WI et al (2014) Trans-oral brush biopsies and quantitative PCR for EBV DNA detection and screening of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 150(4):602–609

    Article  PubMed  Google Scholar 

  19. Lam JW, Chan JY, Ho WK et al (2016) Use of transoral nasopharyngeal brush biopsy for Epstein-Barr virus DNA detection of local recurrence of nasopharyngeal carcinoma after radiotherapy. Head Neck 38(Suppl 1):E1301–E1304

    Article  PubMed  Google Scholar 

  20. Leung SF, Zee B, Ma BB et al (2006) Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 24(34):5414–5418

    Article  CAS  PubMed  Google Scholar 

  21. Chen WH, Tang LQ, Guo SS et al (2016) Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era. Medicine (Baltimore) 95(5):e2642

    Article  CAS  Google Scholar 

  22. You R, Liu YP, Lin M et al (2019) Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int J Cancer 145(10):2873–2883

    Article  CAS  PubMed  Google Scholar 

  23. Liu LT, Tang LQ, Chen QY et al (2015) The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 93(4):862–869

    Article  CAS  PubMed  Google Scholar 

  24. Leung SF, Chan KC, Ma BB et al (2014) Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 25(6):1204–1208

    Article  CAS  PubMed  Google Scholar 

  25. Zhang J, Shu C, Song Y et al (2016) Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore) 95(40):e5130

    Article  Google Scholar 

  26. Wang WY, Twu CW, Lin WY et al (2011) Plasma Epstein-Barr virus DNA screening followed by (1)(8)F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer 117(19):4452–4459

    Article  CAS  PubMed  Google Scholar 

  27. Twu CW, Wang WY, Chen CC et al (2014) Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys 89(1):21–29

    Article  PubMed  Google Scholar 

  28. Chan ATC, Hui EP, Ngan RKC et al (2018) Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol 36(31):3091–3100

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, China

    Fen Xue & Xiayun He

Authors
  1. Fen Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiayun He
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China

    Tao Huang

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Xue, F., He, X. (2020). Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review. In: Huang, T. (eds) Precision Medicine. Methods in Molecular Biology, vol 2204. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0904-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0904-0_9

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0903-3

  • Online ISBN: 978-1-0716-0904-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation